Strato

Strato DNS

Healthcare

Cedrik Britten

Board Member and Chairman of the Audit Committee

Mike Atieh

Chief Technology Officer

Steffen Walter

VP CMC

Ali Mohamed

US Site Head and VP of US Human Resources and Operations

Jessica Mosby

Associate Director

Amir Alpert, Ph.D

Senior Director Corporate Communications

Anja Heuer

Senior Director Clinical Operations

Anja Urban

Business Management

Ankita Patel

Associate Director, Companion Diagnostics

Anya Prokhorova

Friedrich Bohlen

Peter Chambre

Christof Hettich

Nancy Valente

Craig Slingluff

Harald Stock

Heather Mason

Christoph Huber

Carolin Mauch

Associate Director Financial Planning & Analysis

Martin Hofmann

Associate Director Immunology

Norbert Hilf

VP Translational Development

Martina Ott

Associate Director Target Validation

Arun Satelli

Arnd Christ

Chief Financial Officer

Toni Weinschenk

Sonja Dorner

Medical Companies With More Than 10 Employees (Top 10K)

Therapeutics Companies With Fewer Than 1000 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Companies With More Than 10 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Public Companies With More Than 100 Employees

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.

The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.

immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Post-IPO Equity - immatics biotechnologies

Moderna

Bristol-Myers Squibb

Perceptive Advisors

Celgene

Venture Round - immatics biotechnologies

Amgen

dievini Hopp Biotech Holding

Series E - immatics biotechnologies

Series D - immatics biotechnologies

Computer and Software Services and Scientific Services

Tübingen

Baden-Wurttemberg

Germany

Europe

immatics biotechnologies

Oligodendroglioma Treatment Market Size, Segmentation ...

Kidney Cancer Drugs Industry is Expected to Reach $8 Billion ...

Who are the leading innovators in SMAC mimetic peptides for ...

BioSpace Movers & Shakers, Sept. 18

United States

North America

Indonesia

Asia

Turkey

India

HTML5

Google Maps API

Microsoft Outlook

Google Fonts

Wordpress

Bootstrap

Vimeo

jQuery

Google Analytics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Immatics N.V.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Mar 8, 2024 2:05 PM	58feb1cc
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 2:05 PM	e1bbc3b0
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	653af438
crunchbase profile	general	Oct 30, 2024 1:37 PM	c723c7a1
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	c764ccb6
peers	general
news basic	general	Mar 8, 2024 2:05 PM	d84f230e
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:IMMATICS

Immatics

Last Close

9.25

08/11 21:00

Market Cap

1.25B

Beta: -

Volume Today

635.65K

Avg: -